Our team has served the BioHealth Capital Region for over a decade. In those efforts, we’ve also helped to shape and support the vibrant community we’re so proud to call home.
Over the course of recent weeks, communities have closed schools and businesses in the best interest of public health and safety. Rest assured that many companies in our region are working in unison to address Novel Coronavirus.
Image: https://biobuzz-io.cdn.ampproject.org
As the world responds to the COVID-19 pandemic, we are seeing both the value and the need for public-private partnerships to quickly get much-needed medical innovations and technologies to combat infection in the hands of healthcare workers, patients and the general public. In collaboration with government authorities, private companies have stepped up to the plate to manufacture, with urgency, the diagnostic test kits required to identify those with infection. And others, like Johnson & Johnson, are working tirelessly with the aim to identify a vaccine to prevent future outbreaks.
The EIC is organising a special ePitching-session in the light of the current COVID-19 outbreak in an effort to mobilize EIC projects. All EIC-backed SMEs that can contribute to possible solutions to help combat the current pandemic and its consequences and are looking for investment are welcome to apply.
A limited number of EIC-backed up SMEs will then have the chance to show their innovative solutions via an online tool to a jury of investors, including Panakes Partners, Idacapital, Clinical Research Ventures, Monte Carlo Capital, Illumina Ventures, Capricorn Venture Partners, Diffusion Capital Partners on 15 April 2020 from 12.00 till 1.30 pm (CET).
Image: https://en.wikipedia.org/wiki/Coronavirus_disease_2019#/media/File:Novel_Coronavirus_SARS-CoV-2.jpg
Gaithersburg’s Novavax Inc. (NASDAQ: NVAX) has been in the spotlight since January for its work on a novel coronavirus vaccine, but it will need more support to advance the program at the necessary speed, its head of research said Monday.
The Maryland biotech is now moving toward a phase 1 clinical trial after pulling in support from local players.
Two months after it started, “we’re very clearly confident that we can make a vaccine,” said Dr. Gregory Glenn, its president of research and development.
GAITHERSBURG, Md., March 24, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M™ adjuvant, in adults aged 65 and older. Using the Food and Drug Administration’s (FDA) criteria for accelerated approval of seasonal influenza vaccines, the trial evaluated the immunogenicity and safety of NanoFlu compared to Fluzone® Quadrivalent, a U.S.-licensed quadrivalent influenza vaccine.
There is a desperate need for new medicines to treat Covid-19, the disease caused by the novel coronavirus that has shut down much of the world. A vaccine to prevent infection entirely would be even better.
Drug companies and medical researchers are making heroic efforts to deliver new medicines. Several dozen are now in development, and you can see highlights of those efforts here. Studies so far are mostly small and lack real control groups, making it hard for researchers to be sure of their conclusions.
The BioHealth Capital Region (BHCR) and its life science ecosystem have a rich and deep history of pioneering scientific innovation, research, development, and commercialization. The region’s history has been written by life science anchor companies, scientific research universities, government research organizations, rich startup culture, and serial entrepreneurs, all of whom have played critical roles in transforming the BHCR into one of the most innovative and productive biocluster in the world.
Image: https://biobuzz.io/
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Thierry Bernard has been namedChief Executive Officer.
Additionally, a Joint Meeting of the Supervisory Board and the Managing Board has resolved to propose Mr. Bernard, who has been with QIAGEN since 2015, for election as Chief Executive Officer and a Managing Director at the next Annual General Meeting, which is set to take place in June 2020, along with the re-election of Roland Sackers as Chief Financial Officer and a Managing Director. The Joint Meeting further resolved to propose the current members of the Supervisory Board to all stand for re-election: Håkan Björklund, Stéphane Bancel, Metin Colpan, Elaine Mardis, Lawrence Rosen and Elizabeth Tallett.
Image: https://corporate.qiagen.com/
Johns Hopkins University’s COVID-19-tracking map has leveled up to show more granular data on the number of confirmed novel coronavirus cases around the globe.
Since January, well before the coronavirus began rapidly infecting people in the United States, a team from Johns Hopkins University had been tracking the virus’ spread in China and other countries worldwide. Now, a little over two months since launching the interactive map, the tool now shows data reflecting real-time confirmed cases in cities and localities across the U.S. and internationally.
Image: https://www.bizjournals.com
(Reuters) – German molecular testing company Qiagen NV (QIA.DE) said on Tuesday it has begun shipping its diagnostic test for COVID-19 to the United States.
The test kit, QIAstat-Dx Respiratory SARS-CoV-2 Panel, requires less than one minute for sample preparation and can deliver results in about one hour, the company said.
Shipments come under a new policy laid out by the U.S. Food and Drug Administration earlier this month to help accelerate the availability of coronavirus diagnostic tests, developed by laboratories and commercial manufacturers during the public health emergency.
